Home > Result Summaries: Compounds > fosamprenavir > Result Summary for APV10028

Result Summary for APV10028

Result Summary

Protocol ID:	APV10028
Clinical Study ID:	APV10028
Official Title:	A Phase I, Open, Randomized, Balanced, Three-Period, Crossover, Steady-State, Pharmacokinetic Study Comparing GW433908 1400mg BID + RTV 100mg BID, GW433908 1400mg BID + RTV 200mg BID, and GW433908 700mg BID + RTV 100mg BID Regimens in Healthy Adult Subjects
Phase:	Phase 1
Study Indications or Diseases:	Infection, Human Immunodeficiency Virus
Generic Name:	fosamprenavir
Trade/Product Name:	Telzer,Telzir,Lexiva
Approved Drug Label:	http://www.gsk.com/products.html
Results Summary:	Click here to download result summary.
Citations:	Abstract: Steady-state amprenavir (apv) pharmacokinetics (pk) are similar between healthy and hiv-infected subjects following gw433908 (908) ± ritonavir (rtv) using population pharmacokinetic (pop pk) analysis. Kim, YH, Hu, C, Wire, MB, Moore, KHP, and Sale, M 5th International Workshop on Clinical Pharmacology of HIV Therapy 4/1/2004 Rome; Italy M.J. Shelton, M.B. Wire, Y. Lou, B. Adamkiewicz, V. Kitchen. Pharmacokinetic (PK) and Safety Evaluation of High Dose Combinations of Fosamprenavir (FPV) + Ritonavir (RTV) (APV10028). 44th ICAAC, 2004. A-451 Abstract: The pharmacokineticinteraction between gw433908 and lopinavir/ritonavir (apv10011 and apv10012). Wire, M B, Naderer, O J, Masterman, A L, Lou, Y , and Stein, D S American Association for the Advancement of Science Annual Meeting and Science Innovation Exposition 2/12/2004 Seattle, WA; USA